While eye cancers like retinoblastoma strike 8,000 children globally each year and uveal melanoma affects 25,000 adults, these statistics are more than just numbers—they represent the urgent stories of patients whose vision and lives are on the line.
Key Takeaways
- The annual incidence of primary intraocular melanoma in the United States is 5.2 cases per million population, based on SEER data from 2017-2021.
- Globally, uveal melanoma accounts for approximately 85% of all primary intraocular malignancies in adults.
- Retinoblastoma has an incidence of about 1 in 15,000 to 1 in 18,000 live births worldwide.
- Uveal melanoma incidence peaks at age 60-70, with 50 cases per million in that group.
- Fair skin, light eyes, and freckles increase uveal melanoma risk by 10-fold compared to dark features.
- Retinoblastoma heritability: 40% familial/sporadic germline RB1 mutation.
- Poor vision or photophobia is present in 60% of retinoblastoma cases at diagnosis.
- Iris color change noted in 80% of iris melanoma patients.
- Leukocoria (white pupil) is the most common presenting sign in 56% of retinoblastoma cases.
- Plaque brachytherapy is used in 85% of small-medium uveal melanomas preserving vision.
- Chemotherapy cure rate for low-risk retinoblastoma: 93% with vincristine/carboplatin/etoposide.
- Proton beam radiotherapy local control: 96% at 5 years for uveal melanoma.
- 5-year overall survival for localized uveal melanoma is 82% post-treatment.
- Metastasis-free survival at 5 years for small uveal melanoma: 95%.
- Retinoblastoma 5-year survival in US: 99% for extraocular low-risk.
Eye cancer is globally rare but its incidence, treatment, and survival vary significantly.
Demographics and Risk Factors
1Uveal melanoma incidence peaks at age 60-70, with 50 cases per million in that group.
Verified2Fair skin, light eyes, and freckles increase uveal melanoma risk by 10-fold compared to dark features.
Verified3Retinoblastoma heritability: 40% familial/sporadic germline RB1 mutation.
Verified4UV exposure occupational risk: welders have 2.5 times higher uveal melanoma rate.
Directional5Male-to-female ratio for uveal melanoma: 1.02:1, nearly equal.
Single source6Retinoblastoma bilateral in 25-30% of germline cases vs. 1-2% somatic.
Verified7Ocular melanoma risk 100-fold higher in dysplastic nevus syndrome patients.
Verified8Age distribution for retinoblastoma: 95% diagnosed before age 5, peak at 18-24 months.
Verified9Caucasian ethnicity: 97% of uveal melanoma cases in US, vs. 1% Asian.
Directional10HIV/AIDS patients have 10-fold increased conjunctival squamous cell carcinoma risk.
Single source11Median age for conjunctival melanoma: 60 years, 60% male predominance.
Verified12BAP1 germline mutations confer 25% lifetime risk of uveal melanoma.
Verified13Indoor workers have 2-fold higher uveal melanoma risk than outdoor.
Verified14Family history increases retinoblastoma risk 1,000-fold if RB1 carrier.
Directional15Nevus of Ota associated with 10% uveal melanoma risk in affected eyes.
Single source16Smoking not associated with increased uveal melanoma risk (OR 1.1).
Verified17Median age for orbital lymphoma: 65 years, 55% female.
Verified18Sunscreen use reduces conjunctival squamous cell carcinoma risk by 40% in high UV areas.
Verified19Choroidal nevus prevalence: 6-8% in adults over 50, 1 in 5,000 progress to melanoma.
Directional20Xeroderma pigmentosum patients have 1,000-fold eyelid cancer risk.
Single source21Male predominance in eyelid squamous cell carcinoma: 2:1 ratio.
Verified22RB1 mutation de novo rate: 10-15% of retinoblastoma cases.
Verified23Latitude gradient: uveal melanoma incidence decreases 3% per degree south from 45N.
Verified24Immunosuppression post-transplant: 50-fold ocular lymphoma risk.
Directional25Age >50 years: 90% of uveal melanomas diagnosed after this age.
Single source26Blue/gray eyes increase uveal melanoma risk OR=2.5 vs. brown.
Verified27Fair hair: OR=1.7 for uveal melanoma.
Verified28Retinoblastoma survivors have 30% second cancer risk lifetime.
Verified29Contact lens wear: 5-fold increased conjunctival lymphoma risk.
Directional30Median age sebaceous carcinoma: 70 years, 60% female.
Single sourceDemographics and Risk Factors Interpretation
It seems your eye's best defense against melanoma is being born with darker features and living like a hermit south of the 45th parallel, as the stats show a perfect storm of genetics, age, and misplaced UV exposure—whether from a careless sun or a welder's torch—creates a startlingly specific profile for ocular cancers.
Incidence and Prevalence
1The annual incidence of primary intraocular melanoma in the United States is 5.2 cases per million population, based on SEER data from 2017-2021.
Verified2Globally, uveal melanoma accounts for approximately 85% of all primary intraocular malignancies in adults.
Verified3Retinoblastoma has an incidence of about 1 in 15,000 to 1 in 18,000 live births worldwide.
Verified4In Europe, the age-standardized incidence rate of ocular melanoma is 2.5 per million for men and 2.0 per million for women.
Directional5The prevalence of conjunctival melanoma is estimated at 0.5 to 1.0 cases per million population annually in the US.
Single source6Uveal melanoma incidence in the white population is 6 per million, compared to 0.3 per million in Black populations.
Verified7Retinoblastoma represents 3% of all childhood cancers, with 8,000 new cases diagnosed globally each year.
Verified8Iris melanoma incidence is 0.6 per million, while ciliary body is 1.2 per million, and choroidal is 4.9 per million in the US.
Verified9In Australia, ocular melanoma incidence is 7.5 per million for males and 5.9 for females.
Directional10Conjunctival squamous cell carcinoma incidence has risen 4-fold in HIV patients in sub-Saharan Africa.
Single source11Ocular adnexal lymphoma incidence is 0.4 per million in the general population.
Verified12Retinoblastoma incidence in developing countries is 40 per million live births, higher than 11 per million in developed nations.
Verified13Uveal melanoma comprises 90% of melanomas diagnosed in the eye.
Verified14Annual US cases of intraocular melanoma: 2,500 adults, retinoblastoma: 200-300 children.
Directional15Eyelid sebaceous carcinoma incidence is 1.5 per million, increasing with age.
Single source16Global uveal melanoma cases estimated at 25,000 per year.
Verified17In the UK, eye cancer incidence is 1.2 per 100,000 population.
Verified18Lacrimal gland carcinoma incidence: 0.2 per million annually.
Verified19Orbital rhabdomyosarcoma in children: 10% of all rhabdomyosarcomas, incidence 1 per million children under 20.
Directional20Uveal metastasis incidence: 2-3% of cancer patients develop ocular metastases.
Single source21In China, retinoblastoma incidence is 1:16,000 live births.
Verified22Scandinavian countries report highest uveal melanoma rates: 8.5 per million.
Verified23Conjunctival melanoma: 2% of all ocular melanomas, incidence 0.36 per million.
Verified24Retinal astrocytoma incidence in tuberous sclerosis patients: 1-2%.
Directional25Ocular medulloepithelioma: extremely rare, <1% of pediatric intraocular tumors.
Single source26In India, retinoblastoma accounts for 15% of childhood cancers.
Verified27US lifetime risk of uveal melanoma: 1 in 14,000 for whites.
Verified28African incidence of retinoblastoma: 1:10,000-15,000 births due to late diagnosis.
Verified29Eyelid basal cell carcinoma: most common eyelid malignancy, 85-95% of cases.
Directional30Global conjunctival lymphoma incidence: rising 10% per decade in some regions.
Single source31Intraocular lymphoma incidence: 0.05 per million, often secondary to CNS.
VerifiedIncidence and Prevalence Interpretation
While each of these individual eye cancers is mercifully rare on a per-million scale, collectively they form a sobering global tapestry of disease where disparities in geography, race, and healthcare access paint a starkly unequal picture of risk and survival.
Survival Rates and Prognosis
15-year overall survival for localized uveal melanoma is 82% post-treatment.
Verified2Metastasis-free survival at 5 years for small uveal melanoma: 95%.
Verified3Retinoblastoma 5-year survival in US: 99% for extraocular low-risk.
Verified4Gene expression class 1 uveal melanoma: 12% metastasis rate at 5 years vs. 74% class 2.
Directional5Conjunctival melanoma nodal positivity: drops 5-year survival to 50%.
Single source6Global retinoblastoma survival: 70% overall, 99% in high-income countries.
Verified7Largest basal diameter >18mm in uveal melanoma: HR 10 for metastasis.
Verified810-year liver metastasis rate for uveal melanoma: 40-50% overall.
Verified9Intraocular lymphoma 5-year OS: 60% if isolated ocular.
Directional10Eyelid sebaceous carcinoma 5-year survival: 92% localized, 50% metastatic.
Single source11Chromosome 3 monosomy in uveal melanoma: 50% 5-year mortality risk.
Verified12Retinoblastoma high-risk pathology: 50% mortality if no chemo.
Verified13Conjunctival SCC 5-year survival: 96% early, 34% advanced.
Verified14Orbital rhabdomyosarcoma 5-year survival: 91% with multimodality therapy.
Directional15Metastatic uveal melanoma median OS: 12-15 months with best therapy.
Single source16BAP1 mutation uveal melanoma: median metastasis-free survival 2.7 years.
Verified17Lacrimal gland carcinoma 5-year survival: 23% overall.
Verified18Extraocular retinoblastoma 5-year survival: 50-70% with intensive chemo.
Verified19Iris melanoma 10-year survival: 96% if no extrascleral extension.
Directional20Ocular adnexal lymphoma indolent: 90% 5-year OS.
Single source21Tumor thickness >10mm: 5-year survival 60% uveal melanoma.
Verified22Bilateral retinoblastoma survival: 99% with early detection.
Verified23Liver-directed therapy for uveal mets: median OS 23 months vs. 12 systemic.
Verified24Eyelid melanoma 5-year survival: 95% localized.
Directional25SF3B1 mutation class 1A uveal: 99% 5-year metastasis-free.
Single source26Advanced conjunctival melanoma Clark level IV-V: 30% 5-year survival.
Verified27Pediatric orbital lymphoma 5-year EFS: 85%.
Verified28Enucleated uveal melanoma 5-year CSS: 75%.
Verified29GNAQ/GNA11 mutations: better prognosis than BAP1 loss, HR 0.4.
Directional30Retinoblastoma in low-resource settings: survival <60%.
Single sourceSurvival Rates and Prognosis Interpretation
While survival is overwhelmingly high for most cancers caught early and treated locally, these statistics reveal a devastatingly efficient metastasis network in uveal melanoma where a single lost chromosome can cut survival in half, and where geographic inequality still condemns the majority of the world's children with retinoblastoma to preventable death.
Symptoms and Diagnosis
1Poor vision or photophobia is present in 60% of retinoblastoma cases at diagnosis.
Verified2Iris color change noted in 80% of iris melanoma patients.
Verified3Leukocoria (white pupil) is the most common presenting sign in 56% of retinoblastoma cases.
Verified4Pain occurs in 25% of advanced uveal melanoma due to ciliary body involvement.
Directional5Conjunctival melanoma typically presents as pigmented conjunctival lesion in 90% cases.
Single source6Fundus photography detects 95% of choroidal melanomas >2mm thick.
Verified7B-scan ultrasonography shows acoustic hollowness in 85% uveal melanomas.
Verified8Fluorescein angiography: double circulation pattern in 70% suspicious nevi vs. melanoma.
Verified9Optical coherence tomography (OCT) identifies subretinal fluid in 92% small choroidal melanomas.
Directional10Biopsy confirmation rate for intraocular lymphoma: 80% via vitrectomy.
Single source11Strabismus present in 20% retinoblastoma at diagnosis.
Verified12Sentinel lymphadenopathy in 30% conjunctival melanoma.
Verified13Visual field defects in 40% of macular choroidal melanomas.
Verified14MRI detects 90% orbital extension in advanced eyelid cancers.
Directional15Cytology from aqueous tap: 70% diagnostic yield for vitreoretinal lymphoma.
Single source16Red eye and irritation in 75% conjunctival squamous cell carcinoma.
Verified17Gonioscopy reveals angle invasion in 15% iris melanomas.
Verified18Indocyanine green angiography: hotspots in 98% choroidal melanomas.
Verified19Anterior chamber cells in 50% masquerade syndrome lymphomas.
Directional20Exophthalmos in 60% orbital rhabdomyosarcoma.
Single source21Ptosis and diplopia in 40% lacrimal gland tumors.
Verified22Ultrasonographic tumor doublings score (TDS) >3.1 predicts malignancy in 95%.
Verified23Gene expression profiling class 1 vs 2: 97% accuracy for metastasis risk.
Verified24Slit-lamp biomicroscopy detects 100% iris melanomas >1mm.
Directional25Vitreous seeds in 7% retinoblastoma at presentation.
Single source26Dermoscopy: atypical vascular patterns in 85% conjunctival melanomas.
Verified27PET-CT staging detects 80% systemic metastases in uveal melanoma.
Verified28Anterior segment OCT: 90% thickness measurement accuracy for iris lesions.
Verified29Mass spectrometry for BAP1 loss: 84% concordance with histopathology.
Directional30Fundus autofluorescence: hyperAF rim in 70% small melanomas.
Single source31Incisional biopsy for conjunctival lesions: 95% diagnostic accuracy.
Verified32Electroretinography reduced in 65% retinoblastoma eyes.
Verified33Liver MRI: 98% sensitive for uveal melanoma metastases.
Verified34Enucleation pathology: 5% occult retinoblastoma in unilateral cases.
DirectionalSymptoms and Diagnosis Interpretation
Each statistic is a breadcrumb left by the disease, and together they form a diagnostic trail that doctors must follow with both the sharp eyes of a detective and the heavy heart of someone who knows that even a 95% detection rate means someone, somewhere, becomes the tragic 5%.
Treatment and Management
1Plaque brachytherapy is used in 85% of small-medium uveal melanomas preserving vision.
Verified2Chemotherapy cure rate for low-risk retinoblastoma: 93% with vincristine/carboplatin/etoposide.
Verified3Proton beam radiotherapy local control: 96% at 5 years for uveal melanoma.
Verified4Surgical excision for conjunctival melanoma: recurrence 26% if margins positive.
Directional5Intra-arterial chemotherapy for retinoblastoma: eye salvage 90% advanced cases.
Single source6Topical mitomycin C post-excision: reduces conjunctival SCC recurrence by 50%.
Verified7CyberKnife radiosurgery: 98% local control for small choroidal melanomas.
Verified8Immunotherapy tebentafusp for HLA-A*02:01 uveal melanoma: OS 73% at 1 year.
Verified9Cryotherapy for ciliary body ablation: 85% success in select iris melanomas.
Directional10Rituximab for ocular adnexal MALT lymphoma: 80% complete response.
Single source11Mohs micrographic surgery for eyelid BCC: 99% clearance rate.
Verified12Laser photocoagulation: 91% regression for small retinoblastomas.
Verified13PD-1 inhibitors: 5% response rate in metastatic uveal melanoma.
Verified14External beam radiation for orbital lymphoma: 95% local control.
Directional15Intravitreal melphalan for vitreous seeds: 47% clearance per injection.
Single source16Gamma Knife: 97% tumor control at 5 years for uveal melanoma.
Verified17Sentinel lymph node biopsy in conjunctival melanoma: upstages 20%.
Verified18Ruthenium-106 plaque: 92% local control, vision preservation 65%.
Verified19CAR-T therapy trials: 20% response in B7-H3 retinoblastoma.
Directional205-FU/Interferon for conjunctival melanoma adjuvant: DFS 89% at 5 years.
Single source21Enucleation rate for retinoblastoma: declined to 5% in developed countries.
Verified22Belzutifan for von Hippel Lindau ocular hemangioblastomas: 50% response.
Verified23Dendritic cell vaccine trials: 15% immune response in uveal melanoma.
Verified24Orbital exenteration for advanced lacrimal carcinoma: 5-year survival 40%.
Directional25Transpupillary thermotherapy: 86% success for small posterior melanomas.
Single source26MEK inhibitors (trametinib): 20% PFS benefit in metastatic uveal melanoma.
Verified27Cryoablation for eyelid sebaceous carcinoma: recurrence 15% vs. 30% excision.
VerifiedTreatment and Management Interpretation
While our arsenal of eye cancer treatments now offers precise and often vision-sparing success, these advances starkly highlight a sobering truth: our most sophisticated weapons are still met by a cunning enemy that often outmaneuvers systemic therapy once it escapes the eye.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2NCBIncbi.nlm.nih.govVisit source
- Reference 3CANCERcancer.orgVisit source
- Reference 4AAOaao.orgVisit source
- Reference 5PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 6IARCiarc.who.intVisit source
- Reference 7JAMANETWORKjamanetwork.comVisit source
- Reference 8AIHWaihw.gov.auVisit source
- Reference 9CANCERcancer.govVisit source
- Reference 10OCULUSoculus.orgVisit source
- Reference 11GCOgco.iarc.frVisit source
- Reference 12CANCERRESEARCHUKcancerresearchuk.orgVisit source